domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -32,3 +32,10 @@ The same VTA dopamine circuit identified for hedonic eating (periLC → VTA_DA
 **Source:** Annals of Internal Medicine 2024, target trial emulation + exenatide RCT
 
 Target trial emulation (real-world data) shows semaglutide associated with significantly lower risk of medical encounters for tobacco use disorder diagnosis compared with other antidiabetes medications, with strongest effect vs. insulins. Phase 2 RCT (exenatide + NRT) showed increased smoking abstinence vs. placebo + NRT, with reduced cravings and withdrawal symptoms. However, dulaglutide + varenicline RCT showed null result, likely due to ceiling effect (adding GLP-1 to already-effective varenicline). Mechanism consistent with VTA dopamine pathway modulation. This extends the reward circuit claim to a third substance type (tobacco), though evidence is mixed compared to AUD and obesity.
+
+
+## Supporting Evidence
+
+**Source:** Qeadan et al., Addiction 2025
+
+Retrospective cohort study of 1.3M patients across 136 US health systems found GIP/GLP-1 RA prescriptions associated with 40% lower opioid overdose rate (IRR 0.60, 95% CI 0.43–0.83) in OUD cohort and 50% lower alcohol intoxication rate (IRR 0.50, 95% CI 0.40–0.63) in AUD cohort. Effects consistent across T2DM, obesity, and combined subgroups. Largest-scale observational evidence for GLP-1 effect on substance use outcomes, though substantial healthy user bias acknowledged.

inbox/archive/health/2026-04-24-qeadan-addiction-glp1-oud-aud-real-world.md

@@ -7,9 +7,12 @@ date: 2025-02-01
 domain: health
 secondary_domains: []
 format: peer-reviewed study
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-24
 priority: high
 tags: [glp-1, GIP, semaglutide, opioid-use-disorder, alcohol-use-disorder, AUD, OUD, addiction, real-world-data, observational, reward-circuit]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content